Teck Resources Ltd (USA) (NYSE:TCK) shares moved down -1.25% in last trading session and ended the day at $3.16. TCK Gross Margin is 16.90% and its has a return on assets of -5.20%. Teck Resources Ltd (USA) (NYSE:TCK) quarterly performance is -56.33%.
Teck Resources Ltd (USA) (NYSE:TCK) will release its fourth quarter 2015 earnings results on Thursday, February 11, 2016 before market open.
Ryder System, Inc. (NYSE:R) ended the last trading day at $50.56. Company weekly volatility is calculated as 3.33% and price to cash ratio as 35.82. Ryder System, Inc. (NYSE:R) showed a weekly performance of -11.03%.
Ryder System, Inc. (NYSE:R) provided details regarding its conference call scheduled for February 2, 2016 at 11:00 a.m. Eastern Time. During the call, management will review fourth quarter and full-year 2015 results and will provide an outlook for 2016. The call will be webcast over the Internet.
On 08 January, Lifevantage Corporation (NASDAQ:LFVN) shares moved down -20.24% and was closed at $7.92. LFVN EPS growth in last 5 year was 18.80%. Lifevantage Corporation (NASDAQ:LFVN) year to date (YTD) performance is -16.81%.
Lifevantage Corporation (NASDAQ:LFVN) announced the appointment of , the company’s President and Chief Executive Officer, and , a new independent director, to its Board of Directors. The election of and brings the number of Directors to seven members and retains the independence of the Board.
Gilead Sciences Inc. (NASDAQ:GILD) shares increased 0.21% in last trading session and ended the day at $96.45. GILD Gross Margin is 87.30% and its has a return on assets of 41.60%. Gilead Sciences Inc. (NASDAQ:GILD) quarterly performance is -3.91%.
On 2 January, Gilead Sciences Inc. (NASDAQ:GILD) has grown to be a leading biotech company in the past few years, mostly on the back of the phenomenal success of its hepatitis C franchise. The drug-maker’s two revolutionary HCV drugs, Harvoni and Sovaldi, are two of the fastest-growing medicines in history, boasting cure rates of 8-24 weeks, down from a prior 24-48 week treatment period. However, the drugs seem to be approaching market saturation, with Gilead predicting flat HCV sales next year.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) caters to the Healthcare space. It has a net profit margin of 9.20% and weekly performance is -11.86%. On the last day of trading company shares ended up at $168.13. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) distance from 50-day simple moving average (SMA50) is 3.31%.
Vetr cut shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from a buy rating to a hold rating in a research report released on Wednesday, MarketBeatreports. They currently have $196.26 price target on the biopharmaceutical company’s stock.